{"success":true,"data":{"pressRelease":{"id":"16414","rtpr_id":"nPn6kpqMSa","ticker":"PEPG","exchange":"NASDAQ","all_tickers":["PEPG"],"title":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG","author":"PR Newswire","published_at":"2026-05-01T02:40:03.627Z","article_body":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG\n\nPR Newswire\n\nNEW YORK, April 30, 2026\n\nNEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims\non behalf of investors of PepGen Inc. (\"PepGen\" or the \"Company\") (NASDAQ:\nPEPG).  Such investors are advised to contact Danielle Peyton at\nnewaction@pomlaw.com (mailto:newaction@pomlaw.com)  or 646-581-9980, ext.\n7980.\n\n(https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.html)\n\nThe investigation concerns whether PepGen and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\n[Click here for information about joining the class action]\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678306-11&h=3460614308&u=https%3A%2F%2Fpomlaw.com%2Flearn-more-form%3Fcompany%3DPEPG&a=%5BClick+here+for+information+about+joining+the+class+action%5D)\n\nOn March 4, 2026, PepGen announced in a press release that \"[t]he U.S. Food\nand Drug Administration (FDA) has placed a partial clinical hold on the\nFREEDOM2-DM1 Phase 2 multiple ascending dose (MAD), randomized,\nplacebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic\ndystrophy type 1 (DM1)\", stating that \"[t]he partial clinical hold questions\nraised by FDA relate to previously submitted preclinical pharmacology and\ntoxicology studies.\"\n\nOn this news, PepGen's stock price fell $1.25 per share, or 18.57%, to close\nat $5.50 per share on March 5, 2026.\n\nThen, on March 30, 2026, PepGen issued a press release announcing \"clinical\ndata from the 5 mg/kg multiple ascending dose cohort (MAD) of the ongoing\nPhase 2 FREEDOM2-DM1 trial in patients with myotonic dystrophy type 1\n(DM1).\"  Although PepGen characterized the data as \"promising,\" analysts\nnoted the lack of meaningful improvement in patients' handgrip strength or\n10-meter walk/run test.\n\nOn this news, PepGen's stock price fell $2.46 per share, or 58.16%, to close\nat $1.77 per share on March 31, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678306-11&h=55567462&u=http%3A%2F%2Fwww.pomlaw.com%2F&a=%C2%A0)\nwww.pomlaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678306-11&h=146919356&u=http%3A%2F%2Fwww.pomlaw.com%2F&a=www.pomlaw.com)\n.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nDanielle Peyton\nPomerantz LLP\ndpeyton@pomlaw.com (mailto:dpeyton@pomlaw.com)\n646-581-9980 ext. 7980\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-pepgen-inc---pepg-302759693.html\n(https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-pepgen-inc---pepg-302759693.html)\n\nSOURCE Pomerantz LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn6kpqMSa","title":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG","author":"PR Newswire","ticker":"PEPG","created":"2026-05-01T02:40:03.627Z","tickers":["PEPG"],"exchange":"NASDAQ","article_body":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG\n\nPR Newswire\n\nNEW YORK, April 30, 2026\n\nNEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims\non behalf of investors of PepGen Inc. (\"PepGen\" or the \"Company\") (NASDAQ:\nPEPG).  Such investors are advised to contact Danielle Peyton at\nnewaction@pomlaw.com (mailto:newaction@pomlaw.com)  or 646-581-9980, ext.\n7980.\n\n(https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.html)\n\nThe investigation concerns whether PepGen and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\n[Click here for information about joining the class action]\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678306-11&h=3460614308&u=https%3A%2F%2Fpomlaw.com%2Flearn-more-form%3Fcompany%3DPEPG&a=%5BClick+here+for+information+about+joining+the+class+action%5D)\n\nOn March 4, 2026, PepGen announced in a press release that \"[t]he U.S. Food\nand Drug Administration (FDA) has placed a partial clinical hold on the\nFREEDOM2-DM1 Phase 2 multiple ascending dose (MAD), randomized,\nplacebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic\ndystrophy type 1 (DM1)\", stating that \"[t]he partial clinical hold questions\nraised by FDA relate to previously submitted preclinical pharmacology and\ntoxicology studies.\"\n\nOn this news, PepGen's stock price fell $1.25 per share, or 18.57%, to close\nat $5.50 per share on March 5, 2026.\n\nThen, on March 30, 2026, PepGen issued a press release announcing \"clinical\ndata from the 5 mg/kg multiple ascending dose cohort (MAD) of the ongoing\nPhase 2 FREEDOM2-DM1 trial in patients with myotonic dystrophy type 1\n(DM1).\"  Although PepGen characterized the data as \"promising,\" analysts\nnoted the lack of meaningful improvement in patients' handgrip strength or\n10-meter walk/run test.\n\nOn this news, PepGen's stock price fell $2.46 per share, or 58.16%, to close\nat $1.77 per share on March 31, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678306-11&h=55567462&u=http%3A%2F%2Fwww.pomlaw.com%2F&a=%C2%A0)\nwww.pomlaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4678306-11&h=146919356&u=http%3A%2F%2Fwww.pomlaw.com%2F&a=www.pomlaw.com)\n.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nDanielle Peyton\nPomerantz LLP\ndpeyton@pomlaw.com (mailto:dpeyton@pomlaw.com)\n646-581-9980 ext. 7980\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-pepgen-inc---pepg-302759693.html\n(https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-pepgen-inc---pepg-302759693.html)\n\nSOURCE Pomerantz LLP\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-01T02:40:03.66765815Z","server_sent_at_ms":1777603203667},"received_at":"2026-05-01T02:40:04.104Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}